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Background: The clinical benefit of clopidogrel, prasugrel and ticagrelol has been attributed to their antiplatelet effects. We studied the different 
impact of clopidogrel, prasugrel and ticagrelol on endothelial function and platelet reactivity in coronary artery disease (CAD) patients.
methods: We consecutively enrolled 45 patients with stable CAD one month after percutaneus coronary intervention (PCI): 15 patients receiving 
prasugrel regimen (10mg/d), 15 patients receiving clopidogrel regimen (75mg/d) and 15 patients receiving ticagrelol regiment (180mg/d). 
Endothelial function was evaluated by flow mediated dilation (FMD) in the brachial artery. High on treatment platelet reactivity was evaluated using 
VerifyNow Assay. VerifyNow reports its results in P2Y12 reaction units (PRU) and the diagnostic cut-off value is 230 PRU.
results: There was no difference between CAD patients in the three treatment groups (clopidogrel vs. prasugrel vs. ticagrelol) in age (55±8y vs. 
58±10y vs. 54±11y, p=0.55), prevalence of male sex (88% vs. 94% vs. 77%, p=0.41), smoking habits (40% vs. 33% vs. 46%, p=0.14), presence of 
diabetes mellitus (53% vs. 21% vs. 16%, p=0.06) and in the presence of multi vessel CAD (43% vs. 43% vs. 62%, p=0.53). Interestingly, subjects 
under clopidogrel treatment had increased PRU compared to subjects under prasugrel and ticagrelol treatment [204(168 to 276) vs. 125 (52 to 
155) vs. 50(7 to 167), p<0.001)]. Importantly, subjects in clopidogrel group had significantly impaired FMD compared to subjects in prasugrel and 
ticagrelol groups (4.76±1.97% vs. 8.66±3.76% vs. 8.68±1.24%, p=0.002). Finally, in the total study population there was an inverse association 
between FMD and PRU (rho=-0.387, p=0.02).
conclusion: Prasugrel and ticagrelol treatment compared to clopidogrel treatment, showed a greater inhibition of platelet activation in CAD 
patients after PCI with a parallel improvement in endothelial function. Further studies are needed to elucidate the impact of prasugrel, ticagrelol and 
clopidogrel treatment on vascular function and atherosclerosis progression.
